India's Cadila Seeks To Cut The Pain Of GLP-1 Injectables As It Goes For Safety Studies Of Novel Oral Compound
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - It may be early days but researchers at the sprawling Zydus Research Center located near the Western Indian city of Ahmedabad are upbeat about their latest finding - a novel orally administered GLP-1 agonist named ZYOG1- now ready to be tested on humans
You may also be interested in...
Novo Nordisk Expects Strong Patient Benefits To Propel Victoza Sales In India But Will Pricing Get In The Way?
MUMBAI - Enthused by better-then-expected performance of its latest GLP-1 agonist Victoza (liraglutide) in the U.S., Novo Nordisk hopes that its new offering will find wide acceptance among Indian diabetologists and endocrinologists as it gears up for a nationwide launch. In addition to the U.S., Canada, India and E.U., Victoza has been introduced in a short span of time in 11 countries and will soon be available in Japan
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).